biostudies-literatureMannion MLVersus ArthritisPCORIManchester Biomedical Research CentreRheumatology Research FoundationChildhood Arthritis and Rheumatology Research AllianceNational Institute for Health Research (NIHR)U.S. Food and Drug AdministrationNational Institutes of HealthNIAMS NIH HHSPurdue PharmaPatient-Centered Outcomes Research InstituteNIH HHS1090-1098https://www.ebi.ac.uk/biostudies/studies/S-EPMC11288784biostudies-literatureUnknown76(8)<h4>Objective</h4>The objective of this study was to compare the effectiveness of a second tumor necrosis factor inhibitor (TNFi) versus a non-TNFi biologic following discontinuation of a TNFi for patients with polyarticular-course juvenile idiopathic arthritis (pJIA).<h4>Methods</h4>Using the Childhood Arthritis and Rheumatology Research Alliance Registry, patients with pJIA who started receiving a second biologic following a first TNFi were identified. Patients were required to have no active uveitis on the index date and a visit six months after the index date. Outcome measures included Clinical Juvenile Arthritis Disease Activity Score with a maximum of 10 active joints (cJADAS10), cJADAS10 inactive disease (ID; ≤2.5) and cJADAS10 minimal disease activity (MiDA; ≤5). Multiple imputatioArthritis care & researchComparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis.PMC11288784K23 AR075874Norman B Gaylis, MD Clinical Research AwardK23 AR08141020747NIHR20330821755Aviran Dagan NTaneja AOrandi AShehab ARafko JRuth NDalrymple ARiordan MWoolnough LFlanagan ENigrovic PTodd CBlakley MMcCurdy DKitcharoensakkul MVerbsky JTheisen ATaber SNassi LHahn TLevy DLapin BWeiser PDedeoglu FFigueroa CMiller MManos COberle EAlmutairi AShenoi SGrim AMatchett DVega-Fernandez PKienzle BHenrickson MStringer ECollinge JPaller AWaite HWhite ACorrell CWong STory HCiaglia KChang-Hoftman ASantiago LZeft AKlein KZhu AHickey KPuplava BDrew JRodgers LMoreno JQuinlan-Waters MSchmeling HRamsey SHong SModica RReed ADu QEdelheit BMoyer ADavis TSchutt CPaul SRothman DTse SSchahn JVerstegen RGoh IBradfield HRodriquez MGriffin TOnel KAllenspach ECorrell CKMarston BSadun RNeely JGilbert MSule SBinstadt BSpencer CCurry MChiraseveenuprapund PChen ABaszis KKlausmeier TBenseler SPonder LFailing CMachado ABingham CDevine RJohnson LJohnson NMa MHoffart CSullivan JHiraki LWeiss JChalom EJanow GHyrich KLPerron MAkinsete ABrothers MDriest KWeiss PCanna SNativ SMurante BRichins SLasky ASyed RSon MBYasin SStevens BAkoghlanian SHarris JLawler CSrinivasalu HDean JCastro DCooper JYomogida KPatrick ARay LLaxer RRosenkranz MMcColl JNanda KBeil EConlon HSmitherman EArdoin SStewart KFox MNewhall LBigley TBohnsack JBarillas-Arias LOgbu EAl Manaa MBaxter SFox EGoswami NCassidy ESabbagh SCartwright VLimenis EKramer SNajafi AStern SHays KLo MOgbonnaya-Whittesley SSinger NVan Mater HCook KWalters HVannoy LLevinsky YLloyd MGuevara MKimura YThomas BFavier LLytch ABehrens EBridges JHamda Natur MThomas NThomas LKearsley-Fleet LChang JMason TAguiar Lapsia CKnight AChang MGoldsmith DRonis TSchneider RHammond TSchlefman ABullock DStewart WBlack CLing NKingsbury DImundo LDeGuzman MWahezi DSoep JSzymanski AHollander MHobday PLeisinger EMellins ELang BHuie LCo DLvovich SMcBrearty KSchulert GGennaro VMohan SSosna DTesher MRupp JMacMahon JGrom AValcarcel TBegezda ARampone KHarel LDhalla MMian ZNasah NToib DTwachtman-Bassett JBecker MMannion MEde KKasinathan SBeukelman TAngeles-Han SSchikler KWalker BSivaraman VMitacek RVandenbergen SFutch-West TRosenwasser NSmith CAlBijadi AVora SSmith JNatter MToledano APRabinovich CLovell DCooper AOliver MPan NHuberts ASiegel DStapp HParsons APatrizi SVarghese CWright TJames KScalzi LMeidan EWilliams CPatel PBermudez-Santiago LSloan ETaylor JFerguson ISpiegel LMcAllister LPatel JHuber ARife ESyverson GCorbin KPandya JKudas OLin CHersh ADeCoste CStevenson RBacha CFeldman BSpitznagle JTwilt MZhao YArmendariz SLentini LReiff DBlackmon BBuckley MStoll MBuckley LFadrhonc SRosado AHuggins JDuncan ELapidus SKafisheh DRiebschleger MOlveda RFerguson PHarry OShirley JSundel RMilojevic DMiettunen PWidrick KHsu JKremer CMuscal ELuca NCohen EDrapeau NBasiaga MHay ALieberman SRubinstein TMcDonald JFogel LSwayne NHiskey MBrunner HDvergsten JHammelev ETate LTing TFair DGlaser DBoneparth ARahimi HRothermel HSutter MGottlieb BGrevich SNocton JPanupattanapong SLaFlam TLi SJones JTambralli AFuhlbrigge RHausmann JLerman MFranklin LJiang YFurey MJackson AHalyabar OValdovinos RMansfield LSaper VVasquez NFennell JAamir RAmarilyo GDissanayake DCanny SAmoruso MWaterfield MMoore TMoore KPooni RDunnock KZhang YReid HTsin CBukulmez HLim LYeung RDe Ranieri DMannion MLJared SWaters ADizon BBalevic SNowicki KLivny RToth MConnor RRiskalla MTaxter ABallinger SHayward KKlein-Gitelman MCannon LHorton DDeSantis EMadison JMurphy AMwizerwa OHenderson LRothschild EPeskin MOakes RTal RTanner TLee PMcDaniels KKessler EAsfaw LMoorthy LThakurdeen TVelez JChang MLSherman MInman CLee ALopez-Pena MWestheuser VLawson EEdens CEl Tal THolland MAdams AGagne SPadam JSymington TKim SAmin SLee TTarvin SWershba ESwaffar CVallee AHorwitz MGerstbacher DWu EKaur RNearanz KBrooks EStingl CStephens ANolan BSeper CIbarra MElder Mvon Scheven EHui-Yuen JRoth-Wojcicki EBernal WLionetti GPrahalad SEberhard AAbulaban KAmbler WChildhood Arthritis and Rheumatology Research Alliance Registry Investigators and the UK Juvenile Idiopathic Arthritis Biologics Register InvestigatorsCron RKahn PRouster-Stevens KSteigerwald KBaluta SGraham TWagner-Weiner LPerfetto JBalboni ISarkissian AYalcindag AKaidar KLong AImlay ADurkee DElzaki YDhanrajani ATorok KDatyner EGironella ASchultz KRogers DAlperin RRandell RSterba Rakovchik YGorry SDelnay NRobinson LMorgan ESheets RSchmitt ERobinson AKovalick LNguyen AFuller JShishov MfalseComparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis.<h4>Objective</h4>The objective of this study was to compare the effectiveness of a second tumor necrosis factor inhibitor (TNFi) versus a non-TNFi biologic following discontinuation of a TNFi for patients with polyarticular-course juvenile idiopathic arthritis (pJIA).<h4>Methods</h4>Using the Childhood Arthritis and Rheumatology Research Alliance Registry, patients with pJIA who started receiving a second biologic following a first TNFi were identified. Patients were required to have no active uveitis on the index date and a visit six months after the index date. Outcome measures included Clinical Juvenile Arthritis Disease Activity Score with a maximum of 10 active joints (cJADAS10), cJADAS10 inactive disease (ID; ≤2.5) and cJADAS10 minimal disease activity (MiDA; ≤5). Multiple imputatio2024-01-01T00:00:00Z2024 Aug2026-03-16T06:44:12.047Z2025-08-15T03:06:17.002ZS-EPMC112887843855694510.1002/acr.25339